Hayley Virgil

Senior Editor, OncLive®
Hayley Virgil heads OncLive's feature article efforts and specializes in social issues and equality in oncology. Prior to joining the company in early 2020, she worked as an editor in numerous industries, including media, marketing, hospitality, and computer science, and freelanced in subjects such as history, culture, and the natural sciences.

Articles

cfMeDIP-seq Provides Opportunity for Early Cancer Detection, Classification, and Monitoring

May 18th 2021

Cell-free methylated DNA immunoprecipitation-sequencing uses plasma cell-free methylomes to detect and classify several types of cancer early on, and provides the opportunity to monitor tumors for response to treatment in noninvasive way.

Role of Adjuvant Chemoradiation Under Study in Gastric Cancer

May 16th 2021

Katelyn M. Atkins, MD, PhD, examines the evolving role of radiotherapy in the treatment of patients with gastric cancer, the subgroups who might derive the most benefit from this approach, and ongoing research efforts that are seeking to address remaining questions with this modality.

CAR T-Cell Therapy UCARTCS1A Shows Early Activity in Relapsed/Refractory Myeloma

May 14th 2021

UCARTCS1A demonstrated early antitumor activity in heavily pretreated patients with relapsed/refractory multiple myeloma in whom previous CAR T-cell therapy and/or transplant had failed, according to preliminary data from the phase 1 MELANI-01 trial.

Whole-Genome Sequencing in Smoldering Myeloma and MGUS Could Predict Outcomes

May 12th 2021

Ola Landgren, MD, PhD, and Francesco Maura, MD, discuss their research with whole-genome sequencing in patients with precursor conditions, and spotlight next steps for research.

Personalized, Adaptable Treatment Strategies May Improve Survival in Metastatic Gastroesophageal Cancer

May 12th 2021

Offering patients with metastatic gastroesophageal tumors a more personalized and adaptable treatment approach using monoclonal antibodies matched to genetic profiles in combination with chemotherapy may result in higher rates of survival compared with historic controls.

Next-Generation Tissue Factor–Targeting ADC XB002 to be Examined in Several Solid Tumors

May 12th 2021

The safety, tolerability, pharmacokinetics, and preliminary antitumor activity of the novel agent XB002 is set to be examined in an upcoming phase 1 clinical trial that is expected to begin the second quarter of 2021.

Acalabrutinib Elicits Early Activity in a Japanese Population With B-Cell Malignancies

May 12th 2021

Acalabrutinib elicited early antitumor activity with acceptable tolerability in a population of Japanese patients with relapsed/refractory B-cell malignancies.

Quadruplet Regimens May Revolutionize Frontline Myeloma Treatment

May 11th 2021

Luciano J. Costa, MD, PhD, shares key updates regarding transplanteligible and -ineligible patients with multiple myeloma, novel triplet and quadruplet regimens that are shifting standards in the frontline setting, and other modalities under active exploration.

Lurbinectedin Takes Center Stage in Second-line SCLC Treatment

May 10th 2021

Neil Morganstein, MD, discusses the impact of lurbinectedin on the SCLC treatment paradigm and future research directions with the agent in this population.

Fulfilling the Promise of Precision Medicine in EGFR-Mutant NSCLC

May 9th 2021

Edward S. Kim, MD, highlights efforts being made to overcome resistance to EGFR TKIs in patients with EGFR-mutated NSCLC and factors to consider when determining sequential treatment.

Shorter Duration of Adjuvant Trastuzumab Shows Long-Term Survival Benefit in Select HER2+ Early Breast Cancer

May 8th 2021

Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be a reasonable option in a large proportion of the real-world HER2-positive population.

Future of SCLC Treatment Lies in Innovative Immunotherapy Combos

May 6th 2021

Ravi Salgia, MD, PhD, discusses pivotal trials that have shaken up the SCLC treatment paradigm and novel immunotherapy regimens under investigation.

Decker Details Key Updates in Radiation for Advanced NSCLC

May 5th 2021

Roy Decker, MD, PhD, discusses the utility of interventional radiology and SBRT in patients with oligometastatic disease and detailed ongoing clinical trials for NSCLC as they relate to radiation therapy.

Research Efforts Focus on Reducing Recurrence in Early-Stage EGFR-Mutant NSCLC

May 4th 2021

Edward S. Kim, MD, highlights the impact of osimertinib in the treatment of patients with EGFR-mutant non–small cell lung cancer, next steps with the agent, and the importance of early genetic testing to provide personalized care.

Unlocking the Potential of SERDs in Advanced ER+ Breast Cancer

May 3rd 2021

The selective estrogen receptor degrader amcenestrant has demonstrated antitumor activity with acceptable safety in patients with estrogen receptor–positive breast cancer.

Key Considerations for Choosing Between Erdafitinib and Enfortumab Vedotin in Urothelial Carcinoma

April 29th 2021

Michael E. Devitt, MD, further underscored the importance of early genomic testing in patients with urothelial carcinoma, shared advice on factors to consider when choosing among second-line and later options, and highlighted enfortumab vedotin combination regimens that are under exploration.

Increased Somatically Acquired Alterations May Lead to More Aggressive Prostate Cancer, Mortality in Black Patients

April 29th 2021

A higher incidence of somatically acquired genetic alterations, including damaging mutations in ZMYM3 leading to genomic instability, as well as deletions in MAP3K7, BNIP3L, RB1, and NEIL3, and gain of MYC, may lead to more aggressive prostate cancer in Black/African American men.

Bringing Individualized Care to Patients With Breast and Ovarian Cancers in the Caribbean

April 26th 2021

Current breast cancer screening practices in the Caribbean exclude the majority of the younger patient population, thereby leaving many cases of breast cancer undiagnosed.

Earlier Administration of Antiandrogens May Further Delay Disease Progression in Nonmetastatic CRPC

April 26th 2021

Natasha Garg, DO, discusses the impact of antiandrogens in the treatment of patients with nonmetastatic CRPC, shared advice for choosing among the available options, and projected what the future paradigm might look like.

Pivotal Trials Address Pressing Questions With CAR T-Cell Therapy in B-Cell Lymphoma

April 22nd 2021

Nilanjan Ghosh MD, PhD, highlights progress made with CAR T-cell therapies in B-cell lymphoma and some ongoing trials generating interest in the field.